Cook MR, et al. - Investigators analyzed 73 patients to estimate the safety and effectiveness of immune checkpoint inhibitor (ICI) therapy in HIV-infected patients with advanced-stage cancer. They included patients with HIV infection being treated with ICIs for advanced-stage cancer. About 62 candidates were given anti-programmed cell death 1 (anti–PD-1) therapy, 6 were prescribed with anti-cytotoxic T-lymphocyte antigen 4 (anti–CTLA-4) therapy, 4 with anti–PD-1/CTLA-4 therapy, and 1 with sequential ipilimumab and nivolumab therapy. They noticed suppression of HIV in 26 of the 28 (93%) with undetectable HIV load. They suggested immune checkpoint inhibitors were a safe, effective, and generally well tolerated treatment option.